Interaction between tumor necrosis factor microsatellite polymorphisms and the HLA-DRB1 shared epitope in rheumatoid arthritis: Influence on disease outcome

Arthritis and Rheumatism

Volumn 42, Issue 12, 1999, Pages 2698-2704

  Mattey, Derek L ^a,c   Hassell, Andrew B ^a   Dawes, Peter T ^a   Ollier, William E R ^b   Hajeer, Ali ^b  

^a Staffordshire Rheumatology Centre   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Staffordshire Rheumatology Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DR ANTIGEN; MICROSATELLITE DNA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; EPITOPES; FEMALE; FOOT; HAND; HAPLOTYPES; HLA-DR ANTIGENS; HUMANS; LOGISTIC MODELS; LYMPHOTOXIN-ALPHA; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033499211     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199912)42:12<2698::AID-ANR28>3.0.CO;2-S     Document Type: Article

References (41)

1. Wordsworth P, Pile KD, Buckley JD, Lanchbury JSS, Ollier B, Lathrop M, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet 1991;51:585-91.
2. Ollier W, Thompson W. Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am 1992;18:741-59.
3. Van Zeben D, Hazes JMW, Zwinderman AH, Cats A, Schreuder GMT, D'Amaro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis: results of a followup study. Arthritis Rheum 1991;34:822-30.
4. Weyand CM, Hicock KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-6.
5. Ollier WER, MacGregor A. Genetic epidemiology of rheumatoid disease. Br Med Bull 1995;51:267-85.
6. Zanelli E, Gonzalez-Gay MA, David CS. Could HLA-DRB1 be the protective locus in rheumatoid arthritis? Immunol Today 1995;16:274-8.
7. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30: 1205-13.
8. Mattey DL, Hassell AB, Plant M, Dawes PT, Ollier WR, Jones PW, et al. Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope. Ann Rheum Dis 1999;58:164-8.
9. Brennan FM, Maini RN, Feldmann M. TNF-α: a pivotal role in rheumatoid arthritis. Br J Rheumatol 1992;21:293-8.
10. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
11. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
12. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
13. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
14. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turestskaya RL. Highly informative typing of the human TNF locus using adjacent polymorphic markers. Genomics 1993;16:180-6.
15. Hajeer AH, Worthington J, Silman AJ, Ollier WER. Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04-bearing haplotypes in rheumatoid arthritis patients. Arthritis Rheum 1996;39:1109-14.
16. Mulcahy B, Waldron-Lynch F, McDermott MF, Adams C, Amos CI, Zhu DK, et al. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 1996;59:676-83.
17. Mu H, Chen JJ, Jiang Y, King M-C, Thomson G, Criswell LA. Tumor necrosis factor a microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope. Arthritis Rheum 1999;42:438-42.
18. Hajeer A, John S, Ollier WER, Silman AJ, Dawes PT, Hassell A, et al. Tumor necrosis factor microsatellite haplotypes are different in male and female patients with RA. J Rheumatol 1997;24:217-9.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol [Diagn] (Stockh) 1977;18:481-91.
21. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
22. Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994;21:1808-13.
23. Thomson W, Ollier WER. Non-radioactive ASO typing for class II. Eur J Immunogenet 1992;19:169-75.
24. Jawaheer D, Ollier WER, Thomson W. Multiplex ARMS-RFLP: a rapid and simple method for HLA-DR4 subtyping. Eur J Immunogenet 1993;20:279-91.
25. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
26. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonfcrroni versus Holm methods. Am J Public Health 1996;86:726-8.
27. Brennan P, Hajeer A, Ong KR, Worthington J, John S, Thomson W, et al. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility among women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1997;40: 1383-6.
28. Pociot F, Molvig J, Wogensen L, Worsaae H, Daboge H, Back L, et al. A tumor necrosis factor β gene polymorphism in relation to monokine secretion and insulin dependent diabetes mellitus. Scand J Immunol 1991;33:37-49.
29. Pociot F, Briant L, Jongeneel CV, Molvig J, Worsaae H, Abbal M, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNFα and TNFβ by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:224-31.
30. Espersen GT, Vestergaard M, Ernst E, Grunnet N. Tumour necrosis factor α and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity. Clin Rheumatol 1991;10:374-6.
31. Altomonte L, Zoli A, Mirone L, Scolieri P, Magaro MJN. Serum levels of interleukin-1β, tumor necrosis factor-α and interleukin-2 in rheumatoid arthritis - correlation with disease activity. Clin Rheumatol 1992;11:202-5.
32. Vreugdenhil G, Lowenberg B, Vaneijk HG, Swaak AJG. Tumor necrosis factor α is associated with disease activity and the degree of anaemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22:488-93.
33. Beckham JC, Caldwell DS, Peterson BL, Pippen AMM, Currie MS, Keefe FJ, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor α, soluble interleukin 2 receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61.
34. Manicourt D-H, Triki R, Fukuda K, Devogelaer J-P, Nagant de Deuxchaisnes C, Thonar EJ-MA. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis: relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993;36:490-9.
35. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
36. Bouma G, Crusius JBA, Oudkerk Pool M, Kolkman JJ, von Blomberg BME, Kostense PJ, et al. Secretion of tumor necrosis factor α and lymphotoxin α in relation to polymorphism in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel diseases. Scand J Immunol 1996;43:456-63.
37. Wichelow CE, Hitman GA, Raafat I, Bottazzo GF, Sachs JA. The effect of TNF*B gene polymorphism on the TNF-α and -β secretion levels in patients with insulin-dependent diabetes mellitus and healthy controls. Eur J Immunogenet 1996;23:425-35.
38. Zipp F, Weber F, Huber S, Sorgin S, Czlonkowska A, Holler E, et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-α by HLA-DR2+ T cells. Ann Neurol 1995;38:723-30.
39. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
40. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 1997;3:189-95.
41. Akatsuka H, Okubo M, Ishida H, Chibo K, Imanishi K, Uchiyama T, et al. Synovial mononuclear cells consist with T cells which produce high levels of tumor necrosis factor α. Microbiol Immunol 1997;41:367-70.